Abicipar
Pegol (Macular Edema and Macular Degeneration) - Forecast and Market
Analysis to 2023
"The Report Abicipar
Pegol (Macular Edema and Macular Degeneration) - Forecast and Market
Analysis to 2023 provides information on pricing, market analysis,
shares, forecast, and company profiles for key industry participants.
- MarketResearchReports.biz"
Description
Abicipar Pegol (Macular Edema
and Macular Degeneration) - Forecast and Market Analysis to 2023
Summary
Macular Edema is a condition
where fluid accumulates on the macula, leading to vision impairment
or in severe cases even vision loss. The three main types of ME are
diabetic macular edema (DME), and macular edema following either a
central or branch retinal vein occlusion (ME-CRVO and ME-BRVO).
Age-related macular degeneration (AMD) is a painless eye condition
which leads to gradual, irreversible, loss of central vision, and is
one of the leading causes of blindness among people aged 50 and over
in the developed world. Currently the ME and AMD markets are
dominated by the use of anti-VEGF monotherapy, however, in recent
years, corticosteroid implants have been reaching the ME market which
could challenge the stronghold these drugs have in this sector. The
AMD market will see the arrival of the first therapies to treat dry
AMD, fulfilling a huge unmet need in the management of this retinal
disease, and these first-in-class therapies will strongly drive the
market growth over the next ten years. The launch of wet AMD
adjunctive therapies will also see a significant change in the
treatment of AMD patients and have a positive impact on the market
growth.
Allergans abicipar pegol is a
novel, long-acting anti-VEGF drug that is based on the DARPin
technology. It is undergoing clinical development as a potential
treatment for patients with wAMD, and a Phase III clinical trial is
expected to begin in Q2 2015.
View
Full Report at http://www.marketresearchreports.biz/analysis/247098
Scope
- Overview of Macular Edema
and Macular Degeneration, including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines as well as an overview
on the competitive landscape.
- Detailed information on
Abicipar Pegol including product description, safety and efficacy
profiles as well as a SWOT analysis.
- Sales forecast for Abicipar
Pegol for the top country from 2013 to 2023.
- Sales information covered
for the US, France, Germany, Italy, Spain, UK and Japan
Reasons
to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return.
- Stay ahead of the
competition by understanding the changing competitive landscape for
Macular Edema and Macular Degeneration.
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential.
- Make more informed business
decisions from insightful and in-depth analysis of Abicipar Pegol
performance.
- Obtain sales forecast for
Abicipar Pegol from 2013-2023 in top 7 countries (the US, France,
Germany, Italy, Spain, UK and Japan).
Download
Detail Report With Complete TOC at
Table
of Content
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 10
2 Introduction 11
2.1 Related Reports 12
3 Disease Overview 14
3.1 Macular Degeneration Overview 14
3.1.1 Etiology and Pathophysiology 16
3.1.2 Classification 20
3.1.3 Symptoms and Diagnosis 21
3.2 Macular Edema Overview 25
3.2.1 Etiology and Pathophysiology 26
3.2.2 Classification 29
3.2.3 Symptoms and Diagnosis 30
4 Disease Management 33
4.1 Diagnosis and Treatment Overview 33
4.1.1 Macular Edema Diagnosis 33
4.1.2 Macular Degeneration Diagnosis 33
4.1.3 Treatment Guidelines and Leading Prescribed Drugs 34
4.1.4 Clinical Practice 36
5 Competitive Assessment 50
5.1 Overview 50
Browse
Latest News at http://www.marketresearchreports.biz/articles
About
Us
MarketResearchReports.biz is
the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Browse
Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz
Contact
Us
Office:
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA: Canada Toll Free:
866-997-4948
No comments:
Post a Comment